DelveInsight’s “Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Major Depressive Disorder market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Major Depressive Disorder drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Major Depressive Disorder treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Major Depressive Disorder: An Overview
Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders. It has been projected by the World Health Organization to be the leading cause of disease burden in high-income countries by 2032. Major depressive disorder is characterized by persistent sadness, loss of interest or pleasure, low energy, worse appetite and sleep, and even suicide, disrupting daily activities and psychosocial functions.
It is diagnosed when an individual has a persistently low or depressed mood, anhedonia or decreased interest in pleasurable activities, feelings of guilt or worthlessness, lack of energy, poor concentration, appetite changes, psychomotor retardation or agitation, sleep disturbances, or suicidal thoughts. As per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), an individual must have five of the above-mentioned symptoms, one of which must be a depressed mood or anhedonia causing social or occupational impairment, to be diagnosed with Major Depressive Disorder.
The treatment strategies for depression consist of both pharmacological and non-pharmacological options, including psychotherapy, electroconvulsive therapy, and transcranial magnetic stimulation. In recent years, psychotherapy has been shown to affect depression, including attenuating depressive symptoms and improving quality of life. Therefore, several practice guidelines increasingly recommend psychotherapy as a monotherapy or in combination with antidepressants.
Major Depressive Disorder Market Key Facts
-
In 2021, the total 12-month prevalent cases of Major Depressive Disorder in the 7MM exceeded 48 million, out of which the highest 12-month prevalent cases were observed in the United States. The EU5 countries accounted for more than 20 million cases as a whole in 2021.
-
In 2021, there were about 4.8 million Refractory (or TRD) cases of Major Depressive Disorder in the United States. The overall refractory cases of Major Depressive Disorder in the US are subject to increase in the coming years.
Major Depressive Disorder Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Major Depressive Disorder pipeline therapies. It also thoroughly assesses the Major Depressive Disorder market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Major Depressive Disorder drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Major Depressive Disorder Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Major Depressive Disorder epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Major Depressive Disorder epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Major Depressive Disorder Epidemiology, Segmented as –
-
12 Months Prevalent Cases of Major Depressive Disorder in the 7MM [2019–2032]
-
Severity-specific Cases of Major Depressive Disorder in the 7MM [2019-2032]
-
Gender-specific Prevalence of Major Depressive Disorder in the 7MM [2019-2032]
-
Refractory (or TRD) Cases of Major Depressive Disorder in the 7MM [2019–2032]
Major Depressive Disorder Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Major Depressive Disorder market or expected to be launched during the study period. The analysis covers the Major Depressive Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Major Depressive Disorder drugs based on their sale and market share.
The report also covers the Major Depressive Disorder pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Major Depressive Disorder companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Major Depressive Disorder Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/major-depressive-disorder-market
Major Depressive Disorder Therapeutics Analysis
Selective serotonin inhibitors (SSRI), Serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin modulators, and tricyclic antidepressants are currently approved classes of therapies for treating Major Depressive Disorder. In the past few decades, most antidepressant discoveries focused on finding faster, safer, and more selective serotonin or norepinephrine receptor targets. In addition, there is an urgent need to develop new approaches to obtain more effective, safer, and faster antidepressants. Several drugs have been approved for Major Depressive Disorder by regulatory authorities including TRINTELLIX, FETZIMA, and REXULTI, among others.
Recently, the US FDA approved AUVELITY (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of Major Depressive Disorder in adults in August 2022 and VRAYLAR (cariprazine) as an adjunctive therapy to antidepressants for the treatment of Major Depressive Disorder in December 2022.
To improve the treatment scenario, several major pharma and biotech companies are developing therapies for Major Depressive Disorder. Currently, SAGE Therapeutics is leading the therapeutics market with its Major Depressive Disorder drug candidates in the most advanced stage of clinical development.
Latest Clinical, Commercial, and Regulatory Developments in the Major Depressive Disorder Therapeutics Market
-
On 5 June 2023, ANeuroTech announced that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a pivotal Phase IIIB trial of ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder. Phase IIIB will include secondary endpoints of improvements in cognitive function and the ability to feel pleasure, the first time these have been included in an anti-depression drug clinical trial. ANeuroTech expects to begin the trial later this year.
-
On Feb. 06, 2023, Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of the Major Depressive Disorder and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with MDD and PPD.
-
On December 06, 2022, Vistagen (NASDAQ: VTGN) announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of PH10, one of the Company’s investigational nasal sprays, for the treatment of the Major Depressive Disorder.
Major Depressive Disorder Companies Actively Working in the Therapeutics Market Include
AbbVie, Alto Neuroscience, Arrivo Bioventures, Axsome Therapeutics, BioLite Inc., BlackThorn Therapeutics, Inc., Bristol-Myers Squibb, Chase Therapeutics, Fabre-Kramer Pharmaceuticals, Forest Laboratories, Gedeon Richter, GH Research, Intra-Cellular Therapies, Janssen Research & Development, Luye Pharma, Minerva Neurosciences, Neumora Therapeutics, Inc., Neurocrine Biosciences, Novartis, Otsuka Pharmaceutical Co., Ltd., Pherin Pharmaceuticals, Praxis Precision Medicines, Relmada Therapeutics, SAGE Therapeutics, Sirstei Pharmaceuticals, Takeda, Takeda Pharmaceuticals, VistaGen Therapeutics, and others.
Emerging and Marketed Major Depressive Disorder Therapies Covered in the Report Include:
ABV-1504: BioLite Inc., ALTO-300: Alto Neuroscience, AXS-05: Axsome Therapeutics, Brintellix: Takeda Pharmaceuticals, CAPLYTA (Lumateperone): Intra-Cellular Therapies, CTC-501: Chase Therapeutics, Fetzima: Forest Laboratories, LY03005: Luye Pharma, MIJ821: Novartis, MIN-202 (Seltorexant): Janssen Pharmaceuticals/Minerva Neurosciences, NBI-1065845: Neurocrine Biosciences, NMRA-140: Neumora Therapeutics, Inc./BlackThorn Therapeutics, Inc., OPC-64005: Otsuka Pharmaceutical Co., Ltd., PDC-1421: BioLite Inc, PRAX-114: Praxis Precision Medicines, REL-1017: Relmada Therapeutics, Rexulti: Otsuka Pharmaceuticals, SAGE-217: Sage Therapeutics, Seltorexant: Minerva Sciences, SP-624: Arrivo Bioventures/Sirstei Pharmaceuticals, SPL026: Small Pharma, SPRAVATO (Esketamine): Janssen Research & Development, Travivo: Fabre-Kramer Pharmaceuticals, Vraylar (Cariprazine): AbbVie, Zuranolone (SAGE-217/BIIB125): SAGE Therapeutics, and many more.
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/major-depressive-disorder-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Major Depressive Disorder Competitive Intelligence Analysis
4. Major Depressive Disorder Market Overview at a Glance
5. Major Depressive Disorder Disease Background and Overview
6. Major Depressive Disorder Patient Journey
7. Major Depressive Disorder Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Major Depressive Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Major Depressive Disorder Unmet Needs
10. Key Endpoints of Major Depressive Disorder Treatment
11. Major Depressive Disorder Marketed Therapies
12. Major Depressive Disorder Emerging Drugs and Latest Therapeutic Advances
13. Major Depressive Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Major Depressive Disorder Market Outlook (In US, EU5, and Japan)
16. Major Depressive Disorder Companies Active in the Market
17. Major Depressive Disorder Access and Reimbursement Overview
18. KOL Views on the Major Depressive Disorder Market
19. Major Depressive Disorder Market Drivers
20. Major Depressive Disorder Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/major-depressive-disorder-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Failed Back Surgery Syndrome Market
“Failed Back Surgery Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Failed Back Surgery Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Failed Back Surgery Syndrome market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices